Radiation-induced changes in volume and CT number of gross tumour volume and parotid glands during the course of IMRT for head and neck cancers by ATHIYAMAAN, Mariappan Senthiappan et al.
39
ORIGINAL ARTICLE
Address for correspondence:
MS Athiyamaan, MD, DNB
Department of Radiation Oncology, Father 
Muller Medical College, Mangalore, India
e-mail: athiya4u@yahoo.com
Mariappan Senthiappan Athiyamaan1, Abdul Gaffor Hasib1,  
Chintamani Hanumantharao Sridhar1, Prabhu Sudhir2
1Department of Radiation Oncology, Father Muller Medical College, Mangalore, India
2Department of Community Medicine, Father Muller Medical College, Mangalore, India
Radiation-induced changes in volume 
and CT number of gross tumour volume 
and parotid glands during the course  
of IMRT for head and neck cancers
ABSTRACT
Introduction. The CT number (CTN) for tumours and organs at risk can change with radiation therapy, which can 
be an early indicator for radiation response. This study investigates the correlation of radiation-induced changes in 
volume and CTN in gross tumour volume (GTV) and parotid glands (PG) during the course of intensity-modulated 
radiation therapy (IMRT) in head and neck cancers (HNC).
Materials and methods. Re-CT scans were acquired at four weeks for 71 patients with stage II IVb HNC treated 
with chemoradiation. The changes in volumes and CTN of the GTV primary, GTV node, and PG at four weeks of 
radiation were analysed. Pearson’s correlation was used to assess any association between CTN change and 
volume reduction of the GTVs and PGs.
Results. The volumes of the GTVs and the ipsilateral PG and contralateral PG were reduced during the 
course of the radiation therapy after four weeks with mean volume shrinkage of 26.30 ± 7.66 (p < 0.0001), 
32.09 ± 37.2 (p < 0.04), 8.38 ± 1.61 (p < 0.0001), and 9.10 ± 1.81 cm3 (p < 0.0001), respectively, and the mean 
CTN reduced by 2.50 ± 5.4, 1.79 ± 4.12, 1.90 ± 3.57, and 1.99 ± 3.54 HUs, respectively. For GTVs, the CTN 
and GTV volume decreases were found to be positively correlated, but the relationship was weak. However, no 
noticeable correlation was observed between the CTN change and the volume change in both PGs. 
Conclusions. The CTN changes in GTVs and PGs during delivery of radiation for HNC are measurable and patient 
specific. The CTN can be reduced in GTVs and PGs with a reasonable correlation between the mean CTN and 
volume reductions in GTVs, but with no correlation with PGs.
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Introduction
The standard treatment of head and neck cancers 
is intensity-modulated radiation therapy (IMRT) with 
image guidance [1–9]. Image guidance is used to ac-
count for interfractional variations for setup uncertainty 
as well as anatomical changes. The changes in the tu-
mour volumes and organ at risk (OAR) constitute the 
anatomical changes that account for the major inter-
fractional variations that occur during the delivery of 
a radiation course for head and neck cancers (HNC) [1, 
10]. However, image-guided radiation therapy cannot 
completely account for these changes. Hence, adaptive 
radiotherapy has been introduced [11, 12] in which the 
treatment plan is revised and then delivered based on 
changes in tumour and organ at risk anatomy [13, 14]. 
The timing of adaptive re-planning during the course 
of RT delivery is still an unsolved issue. Brown et al. 
considered re-planning at week 4 of radiation therapy 
for oropharyngeal cancer patients with neck nodes [15].
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The CT number (CTN) for the tumour and organs 
at risk can change after radiation therapy. The change in 
CTN could be an early indicator for radiation response 
and local control [16–19]. Howells et al. [18] reported 
that decreased normal liver tissue density correlated 
with RT dose with stereotactic body radiation (SBRT) 
in liver cancer. Palma et al. quantitatively analysed the 
decrease in normal lung density in SBRT lung tumours 
and observed the relation with CTN [17]. Diot et al. re-
ported the change in CTN in relation to radiation dose 
in SBRT lung [16]. Mayer et al. found the CT number 
reduction and its association with local control in lung 
cancer [19].
In our study, we investigated the changes in CT num-
ber for gross tumour and the parotid glands according to 
the re-CT scan done at four weeks/20 fractions in HNC 
patients treated with chemoradiation, and examined 
how these changes are associated with the anatomical 
changes observed.
Materials and methods
The study was carried out on pathologically proven 
HNC patients coming to the radiation department in 
our institute from June 2012 to July 2016. The 72 pa-
tients included in the study were staged according to 
TNM staging system, AJCC, 7th edition. Immobilisation 
was done using thermoplastic masks that were custom 
made to fit the individual patients. The mask was at-
tached to the base plate to fixate the patient and serve 
as a head support. Contrast-enhanced CT scans were 
acquired using GE 16-slice spiral ELITE CT scanner 
with 2.5-mm slice thickness from base of the skull to 
upper mediastinum. 
IMRT plans with seven beams with MLC of 40 pairs 
with 1 cm width at isocentre were optimised. Dose cal-
culation was based on anisotropic analytical algorithm 
(AAA) (version 13.0.26), with the intent of predicting 
the delivery dose to the patient. The optimisation was 
based on dose constraints according to RTOG guide-
lines with respect to tumour coverage and minimisation 
of dose to the organ at risk (OAR). IMRT plans were 
generated and approved for each patient on the treat-
ment planning system ECLIPSE version 8.6, 13 (Varian 
medical system, Palo Alto, CA). For all patients, gross 
tumour volume (GTV P) and nodal disease (GTV N) 
were treated with 6 MV Varian DBX to a dose of 66– 
–70 Gy in 35 fractions with microscopic disease addressed 
with 50–54 GY of radiation, along with 4–6 cycles of 
concurrent sensitiser with cisplatin ± targeted therapy. 
A repeat CT scan was acquired at end of 20th frac-
tion/4 weeks. The GTV P and GTV N, ipsilateral and 
contralateral parotid glands were contoured into the 
repeat CT images to obtain three-dimensional tumour 
volumes, with an effort to minimise the variation in 
contour delineation. The delineation uncertainty should 
not affect the observed results because we are focusing 
at the changes in the mean CTNs only. Changes in the 
GTV of tumour and the nodes between these two CT 
images were analysed. TVRR, defined as the percentage 
reduction of the GTV in relation to the pre-RT GTV, 
where TVRR = (Pre-RT GTV–Mid-RT GTV)/Pre-RT 
GTV, was obtained.
Data analysis
ECLIPSE version 13.0.26 planning software was 
used to analyse the generated contours of the GTV and 
parotid glands. The CTN (in HU) in every voxel inside 
the contoured structure were specified. The mean CTN, 
maximum CTN, and standard deviation of the tumour 
volume GTV and OAR were recorded. Dose volume 
calculation model AAA.13.0.26 was used to measure the 
volume of GTV and OARs. –400 HU was a reasonable 
cut off point to separate tissue and air in the head and 
neck region [6]. CTNs below –400 HU were excluded 
from data analysis in GTV. The changes in the tumour 
volume, mean and max CTN of GTV P, GTV N, and 
both the parotid glands four weeks after the start of 
radiation treatment were also analysed.
Results
A total of 71 patients diagnosed with head and neck 
cancer receiving treatment at our institute were included 
in the study. Twenty-five (35%) patients were in the age 
group 51–60 years, and 19 (27%) were in the age group 
41–50 years. Fifty-six (78%) were males and 15 (22%) 
were females. The ratio of male:female was 3.54:1.
Of the total patients studied, 25 (35%) were dia-
gnosed with carcinoma oropharynx, 20 (28%) had hy-
popharyngeal cancer, 16 (22.5%) had oral cavity cancer, 
10 (14%) had nasopharyngeal cancer, and one was 
diagnosed with metastasis of unknown origin with neck 
nodes. Of the 70 patients staged as per TNM staging, 
43 (61%) patients had stage IVa malignancy, 22 (31%) 
had stage III malignancy, three had stage II disease, and 
two had stage IVb disease. 
Of the total patients studied, 65 patients (91.5%) 
received 70 Gy/35 fractions, and six patients (8.5%) 
received 66 Gy/33 fractions of radical IMRT. Various 
radiation schedules with sensitiser agents used in the 
study are listed in Table 1. 
Dosimetric analysis recorded for the GTVs and the 
OARs are listed in Table 2. For the 70 patients with GTV 
P and GTV N, the doses Dmean [Gy] were 70.11 Gy and 
71.11 Gy, respectively. The mean doses for ipsilateral 
parotids and contralateral parotids for all patients were 
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Table 1. Treatment plan
Treatment plan Number Percentage
Cetuximab + cisplatin + radiation 
(70 Gy/35#)
3 4.22
Nimotuzumab + cisplatin  
+ radiation (70 Gy/35#)
3 4.22
Paclitaxel + cisplatin + radiation 
(70 Gy/35#)
1 1.40
Docetaxel + cisplatin + radiation 
(70 Gy/35#)
1 1.40
Cisplatin + radiation (70 Gy/35#) 57 80.28
Cisplatin + radiation (66 Gy/33#) 6 8.45
Total 71 100
Table 2. Dosimetric parameters of volumes and organs at risk
Volume/Organ at risk Dmean [Gy]
GTV primary 70.90
GTV node 71.11
Ipsilateral parotid 29.88
Contralateral parotid 25.42
Spinal cord 22.93
29.88 Gy and 25.42 Gy, respectively. The mean dose for 
spinal cord was 22.93 Gy.
For all the 71 patients in the study, the mean 
volume reductions (± SD) for GTV primary and 
GTV node were 26.30 ± 7.66 (p < 0.0001) and 
32.09 ± 37.2 cm3 (p < 0.04), respectively. The mean 
volume reductions for ipsilateral parotid and contralat-
eral parotid glands are 8.38 ± 1.61 cm3 (p < 0.0001) 
and 9.10 ± 1.81 cm3 (p < 0.0001), respectively, which 
amounts to 36.10% and 38.29% reduction from initial 
volume, respectively. The mean volumes of pre-RT 
and mid-RT GTV P were 56.69 cm3 (± 12.16 cm3) and 
26.7 cm3 (± 7.55 cm3), respectively. The mean Tumour 
Volume Reduction Rate (TVRR) relative to pre-RT 
baseline was –46.38%. The mean volumes of pre-RT 
and mid-RT GTV N were 48.28 cm3 (± 41.91 cm3) and 
16.18 cm3 (± 9.28 cm3), respectively. The TVRR relative 
to pre-RT baseline was –66.48%.
There were detectable changes in CTN seen from 
the re-CT scan acquired after 20 fractions in most of 
the patients, while there were significant anatomical 
changes in the volumes of both GTV and the parotid 
glands. The mean CTN changes in GTV P and GTV 
N were 2.50 ± 5.4 and 1.79 ± 4.12 HU, respectively. 
Similarly, the mean CTN changes in ipsilateral pa-
rotid and contralateral parotids were 1.90 ± 3.57 and 
1.99 ± 3.54 HU, respectively. The changes noted were 
highly patient specific. Out of the 70 patients with 
clinically and radiologically detectable GTV Primary, 
12 had a significant reduction in mean CTN of GTV P 
of more than 20 HU, with 50 patients showing a varied 
moderate reduction in mean CTN of GTV P, and with 
a total of 88.57% patients showing definitive reduc-
tion in mean CTN. Similarly, around eight among the 
43 patients with clinically and radiologically proven neck 
nodes GTV N had a significant reduction in mean CTN 
of more than 20 HU, 67% of patients showing mild to 
moderate reduction in mean CTN, and with a total of 
86.05% patients showing definitive reduction in mean 
CTN. It is also observed that overall less than 10% of 
the patients had a marginal increase in the mean CTN 
noted in both GTV P and GTV N. It was observed that 
the mean CTN reduction was slightly greater in GTV 
P than in GTV N. 
The correlation of the percentage of volume shrink-
age and mean CTN reduction of ipsilateral parotid 
was 14.85 ± 1.50 and that of contralateral parotid was 
14.65 ± 1.44, showing a mild increased reduction in 
CTN in ipsilateral parotid; however, in patients with 
a significant GTV P volume shrinkage, the mean re-
duction in ipsilateral parotid CTN was greater than the 
contralateral parotid CTN (p = 0.07).
The max CTN changes in GTV P and GTV N were 
36.17 ± 108.2 and 90.41 ± 62.2 HU (p < 0.002), re-
spectively. Similarly, the max CTN changes in ipsilateral 
parotid and contralateral parotid were 90.41 ± 62.2 and 
32.08 ± 67.50 HU, respectively, the reduction being on 
similar lines to that seen in mean CTN reduction of 
ipsilateral parotid.
There was a positive correlation observed between 
the mean CTN reduction and relative volume reduc-
tion for GTV P with a Pearson’s correlation coefficient 
0.136 although the relationship was weak and with a co-
efficient of determination 0.0187 (Fig. 1). Similar posi-
Figure 1. Correlation of CTN (X Values) and volume (Y Values) 
reductions of GTV Primary
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Figure 2. Correlation of CTN (X Values) and volume (Y Values) 
reductions of GTV Node
Figure 3. Correlation of CTN (X Values) and volume (Y Values) 
reductions of ipsilateral parotid gland
tive correlation was observed between the mean CTN 
reduction and relative volume reduction for GTV N 
with a Pearson’s correlation coefficient of 0.073 (Fig. 2). 
However, there was no correlation observed between 
the max CTN reduction and relative volume reduction 
for GTV N.
There was no correlation observed between the CTN 
change and the volume change in both the ipsilateral 
parotid (p = 0.20) (Fig. 3) and contralateral parotid 
glands (p = 0.04) (Fig. 4).
Discussion
Head and neck (H&N) cancer patients undergo 
anatomical change throughout radiation treatment. 
Adaptive radiotherapy (ART) addresses the impact of 
this change on the planned dose distribution. Brown et 
al. [15] concluded that for H&N cancer patients with 
Figure 4. Correlation of CTN (X Values) and volume (Y Values) 
reductions of contralateral parotid gland
neck nodes receiving definitive chemoradiotherapy, 
re-planning may be considered at week 3 of treatment 
for nasopharyngeal cancer and at week 4 for oropharyn-
geal cancer patients. Yang et al. [20] reported that timing 
of ART for H&N cancer patients should be in the fourth 
or fifth week of treatment to facilitate adequate volu-
metric response to radiation while preserving adequate 
treatment time for re-planning. The time for re-CT in 
our study is four weeks/20 fractions. 
Significant tumour and volume regression of both 
parotid glands observed in this study around mid-treat-
ment with radiation are comparable with studies done 
previously [1, 10, 21]. Nishimura et al. [22] reported 
that the volume of the PGs decreased from 43.1 to 
32.0 ml in the third week of a four-week course of IMRT 
(p < 0.001). Fiorentino et al. [23] reported that by the 
20th day of treatment, the PGs had shrunk by 30% of the 
original volume, supporting the hypothesis that, during 
the third week of RT, a check of the PG volume and/or 
a re-plan could be indicated, which was in agreement 
with our research findings showing that the volumes of 
the ipsilateral and contralateral PGs reduced by 36.1% 
and 38.2%, respectively, at the end of four weeks.
Barker et al. [1] reported GTV decrease throughout 
the course of fractionated radiation at a median rate of 
0.2 cm3 per treatment day (range 0.01–1.95 cm3/day), 
and in terms of the percentage of the initial tumour 
volume, the GTVs decreased at a median rate of 1.8% 
per treatment day (range 0.2–3.1%/day). Similar find-
ings were observed in this study with mean volume 
reductions (± SD) for GTV primary and GTV node of 
26.30 ± 7.66 (p < 0.0001) and 32.09 ± 37.2 cm3 (p < 0.04), 
respectively, which corresponds to 2.3% and 3.32% vol-
ume reduction per day, respectively. The mean Tumour 
Volume Reduction Rate (TVRR) relative to pre-RT 
baseline for GTV P was –46.38% (0.4638), and TVRR 
relative to pre-RT baseline for GTV N was –66.48% 
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(0.6648). Yang et al. [20] showed a mean TVRR of 
0.43 in GTV P for oropharyngeal cancer and 0.33 in 
GTV P for hypopharyngeal cancer over a 4–5-week 
period. Hyabin lee et al. [24] reported the mean TVRR 
relative to pre-RT baseline in nasopharyngeal cancer as 
–41.9% (0.419). In this study, we not only noted that the 
TVRR was comparable to that of the above studies, but 
also that the nodal regression was more than the pri-
mary tumour reduction as the increased tumour nodal 
vasculature and oxygenation might have determined the 
volume reduction.
The mean CTN changes observed in both the GTV 
and the parotid glands during the course of radiation 
are highly patient specific. Though around 90% of pa-
tients showed reduction in the mean CTN of the GTV 
P and GTV N, a substantial change was observed only 
at around 20%. Similarly, the mean CTN of the parotid 
glands was also patient specific with a mild increased 
reduction in CTN of ipsilateral parotid; however, in 
patients with a significant GTV P volume shrinkage, 
the mean reduction in ipsilateral parotid CTN was 
greater than the contralateral parotid CTN (p = 0.07). 
Similar reports from Mei Feng et al. [25] and Shouping 
Xu et al. [26] confirm that the CTN changes are highly 
patient specific. This forces us to accept the fact that 
even though all patients received the same dose, the fact 
that the CTN reduction varied implies that the radiation 
dose might be just one of the many factors causing the 
CTN changes.
The tumour and normal structure changes in mean 
CTN during and after radiation are reported in various 
studies. Diot et al. [16] observed an increase in CTN of 
normal lung tissue with an increase in SBRT radiation 
dose until 35 Gy and thereafter remained unchanged. 
With subsequent follow-up for 30 months after RT, the 
rate of CTN increase with dose remained at around 
0.24% per gray. Xu et al. [27] noticed reduction in mean 
CTN in GTV and parotid glands during the delivery 
of fractionated radiotherapy for nasopharyngeal can-
cers. Mayer et al. [19] observed a mean CTN reduction 
of –3 to –36 HU in lung tumour volumes in patients 
treated with conventional fractionation dose up to 
66.6 grays. De et al. [28] reported that the CTN changes 
with radiation dose observed in lung tumours were 
highly patient specific and ranged from 0 to 10 HU/Gy. 
Howell et al. [18] observed the reduced CTN in post 
SBRT normal liver after liver irradiation. Thalacker et 
al. [29] observed the reduction of CTN of white matter 
by 5 HU after brain irradiation.
Mei Feng et al. [25] reported a decrease in mean 
CTN of both tumour and parotid glands during the 
course of radiation in HNC with a fair correlation be-
tween CTN reduction and radiation dose for a subset of 
patients, but also reported that the correlation between 
volume reductions and CTN reductions in both GTV 
and parotid glands were weak. In our study also we 
observe a positive correlation between the mean CTN 
reduction and relative volume reduction for GTV P and 
for GTV N, although the relationship is weak. However, 
there was no correlation observed between the max 
CTN reduction and relative volume reduction for GTV 
N. There was also no correlation observed between the 
CTN change and the volume change in the both the 
ipsilateral parotid and contralateral parotid glands.
The patient-specific CTN changes observed in 
the GTV in this study may be related to the radiation 
response of the individual patient because the doses 
received at the timing of re-CT scan were the same 
for all the patients. The mechanism behind this CTN 
change is still unclear. Yue Cao et al. [30] reported 
an increase in blood volume of the primary tumour 
volume early in the course of RT (after two weeks of 
RT) in HNC patients with local control (median change 
5.1 mL/100 g). This increase is significantly higher than 
the change in blood volume of patients with local failure 
(median change 1.0 mL/100 g). This study suggests that 
an increase in local blood supply, and thereby potentially 
a source of improved tumour oxygenation, may be an 
early positive indicator for predicting the therapeutic 
response at the primary tumour site and disease prog-
nosis of HNC patients. Truong et al. [31] reported that 
the pre-treatment tumour blood flow and the capillary 
permeability were significantly higher in patients who 
achieved loco-regional control than in patients with 
treatment failure. Based on these studies, we infer that 
the CTN reductions in the GTV observed might be 
a result of the increased tumour blood volume. As the 
radiation dose increases, there is shrinkage of GTV, 
whereas there is an increase in the tumour blood vol-
ume, which might make the tumour appear hypodense, 
resulting in the reduction in the CTN of the GTV. The 
tumour cell death as a result of increasing radiation dose 
causes the tumour to shrink, which contributes to the 
reduction in tumour CTN.
The mechanism of radiation-induced CTN change 
in parotid glands is attributed to multiple factors. Heo 
et al. [32] found that age and obesity are correlated with 
the size and the CTN change of the major salivary gland. 
Teshima et al. [33] reported a correlation between de-
creased saliva production and decreased parotid gland 
volume in HNC patients receiving radiation. Stephens 
et al. [34] observed that the damage to the secretary 
cells and the lack of regenerating the acinar cells with 
radiation dose contribute to CTN changes in parotid 
glands. These factors might contribute to the highly 
complex radiation dose dependence noted in CTN 
reduction of both the parotid glands [23].
The radiation-induced CTN changes may be rec-
ognised as an early indicator for radiation response for 
a subset of patients. If this indicator is verified and the 
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mechanism behind is explored, the CTN change can 
potentially be used as a complimentary indicator to be 
added or replace the dosimetric indicators currently in 
use in adaptive radiotherapy in HNC.
Conclusions
The CTN can be reduced in both the tumour vol-
umes (GTV P and GTV N) and in bilateral parotid 
glands during the midway course of radiation therapy 
for HNC. There is a reasonable correlation between the 
mean CTN reductions and volume reductions in GTV 
P and GTV N, but no correlation with both the parotid 
glands. These observations of the CTN changes are 
highly patient specific and may be used as an indicator 
to trigger adaptive radiation therapy for HNC. 
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